Further mechanistic studies demonstrated that immune checkpoint inhibitor therapy initially promotes the amplification of T cell factor 1 (TCF-1)+ thymocyte selection-associated HMGB (TOX)- CD8+ T cells), which are tumour-specific memory cells in TDLNs, These cells subsequently migrated to the TME and peripheral immunity where they differentiate into effector T cells (52). Here, CD8A is linked to neoplasm.